A Randomized, Double-Masked, Sponsor-Unmasked, Ascending Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRM-151 Administered Intravenously to Patients With Idiopathic Pulmonary Fibrosis
Latest Information Update: 22 Apr 2022
At a glance
- Drugs Zinpentraxin alfa (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Promedior; Roche
- 15 Jan 2014 New trial record
- 08 Jan 2014 Exploratory endpoint results were presented at the 2013 Annual Meeting of the American Thoracic Society, according to a Promedior media release.